Abstract: A power system including a first battery pack, a second battery pack, and a power management circuit is disclosed. The first battery pack has a first end and a second end, and has a first battery capacity. The second battery pack has a third end and a fourth end. The third end is coupled to the second end of the first battery pack and provides a low battery voltage. The fourth end is grounded, the second battery pack has a second battery capacity, and the second battery capacity is greater than the first battery capacity. The power management circuit is coupled to the second battery pack to receive the low battery voltage, and provides a component operating voltage to an electronic components based on the low battery voltage.

Abstract: Devices and method for forming a switch including a heater layer including a first heater pad, a second heater pad, and a heater line connecting the first heater pad and the second heater pad, a phase change material (PCM) layer positioned in a same vertical plane as the heater line, and a floating spreader layer including a first portion positioned in the same vertical plane as the heater line and the PCM layer, in which the first portion has a first width that is less than or equal to a distance between proximate sidewalls of the first heater pad and the second heater pad.

Abstract: The invention relates to an anti-cancer vaccine combination. Particularly, the invention relates to a pharmaceutical combination comprising a PD-L1/PD-1 expression inhibitor in combination with a viral antigen-associated vaccine.

Abstract: The invention relates to an anti-cancer vaccine combination. Particularly, the invention relates to a pharmaceutical combination comprising a PD-L1/PD-1 expression inhibitor in combination with a viral antigen-associated vaccine.

Abstract: The invention relates to a method for treating and/or preventing a tumor growth, invasion and/or metastasis by inhibiting an overexpression of PD-L1 in the subject via an autocrine loop. The invention found that PD-L1-modulated p21 and VEGF-C expression via the TGF?1/SMAD4 pathway is responsible for the cancer growth, invasion and metastasis.

Abstract: The present invention provides (poly)peptides, which are recognized by human cytomegalovirus (CMV)-specific immune cells. The present invention further provides a combination of multiple CMV (poly)peptides, comprising at least two different groups of (poly)peptides according to the invention as well as conjugates, comprising said (poly)peptides and/or immune adjuvants thereof. Furthermore, this invention provides mixtures, comprising said (poly)peptides and/or immune cells thereof, which are used to generate CMV-specific immune effector cells with high sensitivity and specificity. In addition, the present invention provides a preparation method of CMV-specific immune effector cells, by using said (poly)peptides, adjuvants, immune cells and/or mixtures thereof to generate anti-CMV immune response.